# Vogenx Inc (VOGX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $31.73, market value $471 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Vogenx Inc reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -0.2%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 157.3%**. A 157.3% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Financial health
- **Current ratio: 0.43** (quick 0.43). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vogenx Inc does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -10.6%** (145.0% above the low). Trading 11% below its 52-week high.
- **RSI (14-day): 89**. An RSI of 89 is in overbought territory; short-term pullbacks are common from here.

Live score and charts: https://foliofundamentals.com/analyzer?s=VOGX · Page: https://foliofundamentals.com/stocks/vogx

Not investment advice.